Nivolumab Plus Radiotherapy in Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
- Status
- TERMINATED
- Phase
- PHASE2
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study
- Status
- COMPLETED
- Phase
- N/A
Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
- Status
- RECRUITING
- Phase
- N/A
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
- Status
- WITHDRAWN
- Phase
- PHASE2
Pembrolizumab-PET Imaging
- Status
- COMPLETED
- Phase
- NA
In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases
- Status
- COMPLETED
- Phase
- N/A
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
- Status
- COMPLETED
- Phase
- N/A
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma
- Status
- COMPLETED
- Phase
- N/A
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE3